# AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

> **NCT05826015** · PHASE1 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Recurrent High Grade Uterine Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Batiraxcept

## Key facts

- **NCT ID:** NCT05826015
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-10-31
- **Primary completion:** 2029-06-03
- **Final completion:** 2034-06-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial did not go forward
- **Last updated:** 2024-10-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05826015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05826015, "AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05826015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*